银诺医药-B(02591)用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出

Core Insights - The company has been actively promoting the global expansion of its core product, Isupravaglutide α, which is intended for the treatment of Type 2 Diabetes (T2D) [1] - The company received approval for the Biologics License Application (BLA) for its core product in the Macau Special Administrative Region of the People's Republic of China, expected by June 2025 [1] - The first prescription for the core product for T2D treatment was issued at the Huabao Medical Center in Macau on September 12, 2025, marking the official commercialization phase of the product in Macau [1]